Is it time to reassess the BDNF hypothesis of depression?
The brain-derived neurotrophic factor (BDNF) hypothesis of depression postulates that a loss of BDNF is directly involved in the pathophysiology of depression, and that its restoration may underlie the therapeutic efficacy of antidepressant treatment. While this theory has received considerable experimental support, an increasing number of studies have generated evidence which is not only inconsistent, but also directly contradicts the hypothesis. This article provides a critical review of the clinical and preclinical studies which have been responsible for this controversy, outlining pharmacological, behavioural and genetic evidence which demonstrates the contrasting role of BDNF in regulating mood and antidepressant effects throughout the brain. I will also review key studies, both human and animal, which have investigated the association of a BDNF single-nucleotide polymorphism (Val66Met) with depression pathogenesis, and detail the number of inconsistencies which also afflict this novel area of BDNF research. The article will conclude by discussing why now is a critical time to reassess the original BDNF hypothesis of depression, and look towards the formation of new models that can provide a more valid account of the complex relationships between growth factors, mood disorders and their treatment.
Groves
J O
JO
The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. james.groves@well.ox.ac.uk
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics / Q000378:metabolism*; D003863:Depression / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D008715:Methionine / Q000235:genetics; D008954:Models, Biological; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D014633:Valine / Q000235:genetics
D019208:Brain-Derived Neurotrophic Factor; D008715:Methionine; D014633:Valine